These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Mycotic aneurysm of the popliteal artery as a complication of intravesical BCG therapy for superficial bladder cancer. Case report and literature review. Witjes JA; Vriesema JL; Brinkman K; Bootsma G; Barentsz JO Urol Int; 2003; 71(4):430-2. PubMed ID: 14646447 [TBL] [Abstract][Full Text] [Related]
23. Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy. Menke JJ; Heins JR Ann Pharmacother; 2000 Apr; 34(4):479-82. PubMed ID: 10772435 [TBL] [Abstract][Full Text] [Related]
24. BCG versus COVID-19: impact on urology. Desouky E World J Urol; 2021 Mar; 39(3):823-827. PubMed ID: 32417996 [TBL] [Abstract][Full Text] [Related]
27. [Diagnosis and management of adverse events occuring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): review of the Cancer Committee of the French Association of Urology]. Neuzillet Y; Rouprêt M; Wallerand H; Pignot G; Larré S; Irani J; Davin JL; Moreau JL; Soulié M; Pfister C; Prog Urol; 2012 Dec; 22(16):989-98. PubMed ID: 23178094 [TBL] [Abstract][Full Text] [Related]
28. [Imaging findings in BCGitis--Bacillus-Calmette-Guérin-Infektion (BCGitis) after intravesical BCG instillation therapy in urothelial carcinoma of the urinary bladder]. Kaufmann S; Amend B; Kruck S; Gakis G; Bedke J; Horger M Rofo; 2015 Aug; 187(8):623-7. PubMed ID: 26218471 [No Abstract] [Full Text] [Related]
29. [Prevention of Bacillus Calmette-Guérin immunotherapy complications]. Colombel M; Picard A Prog Urol; 2008 May; 18 Suppl 5():S105-10. PubMed ID: 18585631 [TBL] [Abstract][Full Text] [Related]
32. Is intravesical chemotherapy for superficial bladder cancer still justified? Okeke AA; Probert JL; Gillatt DA; Schwaibold H BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195 [No Abstract] [Full Text] [Related]
33. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Soloway MS; Jordan AM; Murphy WM Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268 [TBL] [Abstract][Full Text] [Related]
34. Hazardous Drugs in the Urology Workplace: Focus on Intravesical Medications. Hensley D Urol Nurs; 2016; 36(4):183-9. PubMed ID: 29240329 [TBL] [Abstract][Full Text] [Related]
35. Complications of intravesical therapy for urothelial cancer of the bladder. Koya MP; Simon MA; Soloway MS J Urol; 2006 Jun; 175(6):2004-10. PubMed ID: 16697786 [TBL] [Abstract][Full Text] [Related]